President Donald Trump has nominated Alex Azar, a former pharmaceutical executive, to become the next secretary of HHS. The position was vacant after Tom Price, MD, resigned in late September.
President Donald Trump has nominated Alex Azar, a former pharmaceutical executive, to become the next secretary of HHS. The position was vacant after Tom Price, MD, resigned in late September.
Azar’s name had been floated as a front-runner for the position after FDA commissioner Scott Gottlieb, MD, and Veterans Affairs secretary David Shulkin indicated they were satisfied with their current posts and did not want to leave them to lead HHS. Trump confirmed the rumors in a tweet during a trip to Asia.
Happy to announce, I am nominating Alex Azar to be the next HHS Secretary. He will be a star for better healthcare and lower drug prices!
— Donald J. Trump (@realDonaldTrump) November 13, 2017
Azar had been president of the US division of pharmaceutical company Eli Lilly until this January. Before he joined Lilly in 2007, he had been a deputy secretary at HHS under the George W. Bush administration. He also has a legal background that includes working as a clerk to former Supreme Court Justice Antonin Scalia.
As referenced in Trump’s tweet, a goal of his presidency has been to lower drug prices, as he had previously accused drug companies of “getting away with murder.” He also convened a meeting with Representatives from across the aisle to discuss this area of common ground. Rep. Elijah Cummings, D-Maryland, praised the president as “aware of the problem” and “enthusiastic” about solving it.
Considering Azar’s background, his Senate confirmation hearing for appointed to the post of HHS Secretary will likely include tough questions about drug pricing and his ability to regulate his former industry.
If confirmed, he will play a significant role in Trump’s ongoing efforts to dismantle and replace the Affordable Care Act. Azar has been a frequent critic of the law, but in a June interview with Bloomberg TV said that “there are still changes that can be made to make it work a little better than it has been.”
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Similar In-Hospital, Long-Term Survival Rates Found Among Male, Female Patients With AECOPD
March 18th 2024This study analyzed sex differences among patients with acute exacerbations of chronic obstructive pulmonary disease (AECOPD), with findings indicating that female smokers experience worse hospital outcomes despite similar overall survival rates.
Read More
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
AstraZeneca joins efforts to address high drug prices by capping out-of-pocket costs for its inhalers; Opill, the first OTC birth control pill, is now accessible through online sales; expansion prompts questions on the effectiveness and regulation of remote monitoring technology.
Read More